Herpes simplex virus (HSV) causes serious problems in immuno-compromised patients such as those receiving a bone marrow transplant (BMT) for a hematological malignancy. Resistance to acyclovir (ACV) is a growing major concern. Foscarnet is a non-thymidine kinasedependent agent, but the emergence of ACV and foscarnet-resistant HSV requires a new therapeutic approach. We describe a girl treated with cidofovir for a lifethreatening ACV-resistant HSV infection after an unrelated BMT for a relapse of an acute myeloblastic leukemia (AML). Bone Marrow Transplantation (2000) 26, 903-905. Keywords: AML; bone marrow transplantation; herpes simplex virus infection; cidofovir Herpes simplex virus (HSV) infection is the most common viral infection after bone marrow transplant (BMT).
Herpes simplex virus (HSV) infection is the most common viral infection after bone marrow transplant (BMT).
1 Acyclovir (ACV) is the drug of choice for prophylactic and curative treatment of HSV infection. 2 However, the emergence of ACV-resistant HSV infection is a new and challenging problem. Foscarnet is usually effective in this situation. Cross-resistance to ACV and foscarnet has been previously described in patients after BMT. 2, 3 Cidofovir has been recently approved for the treatment of CMV retinitis in acquired immuno-deficiency syndromes. It is the first of a new class of nucleotide antiviral agents with activity against a broad spectrum of herpes viruses. 4 Here, we report, successful treatment of an ACV and foscarnet cross-resistant herpetic infection with cidofovir in a child after an unrelated BMT.
Case report
An 18-month-old girl, was admitted in June 1998 with AML 4 with a t(9;11)(p12;q23). A complete remission was 2 ) and G-CSF 5 g/kg/day started 2 days before chemotherapy. 5 During the neutropenic period following induction chemotherapy, the patient developed a severe mucositis which was slowly but successfully treated with ACV 10 mg/m 2 every 8 h. The two subsequent courses of consolidation were complicated with the same HSV mucositis. No investigations were performed to study the HSV sensitivity to antiviral treatment because of the good prior response to ACV.
After a conditioning regimen including busulfan 120 mg/m 2 /day p.o. in divided doses daily for 4 days (TD: 480 mg/m 2 ), cyclophosphamide 50 mg/kg/day once daily i.v. for 4 days (TD: 200 mg/kg) and anti-lymphocyte serum 5 mg/kg (TD: 20 mg/kg), the patient was transplanted with bone marrow from of an unrelated HLA matched donor. To prevent graft-versus-host-disease (GVHD) she received i.v. cyclosporin (2 mg/kg/day) and methotrexate (15 mg/m 2 day 1 then 10 mg/m 2 on days 3, 6, and 11). Before initiation of the BMT procedure, blood PCR assay for HSV was negative.
At day +5 after bone marrow infusion, a recurrence of HSV mucositis occurred despite prophylaxis with ACV (250 mg/m 2 every 8 h). After a transient improvement related to the end of aplasia (day +15) the HSV lesions extended to the right cheek, the larynx and the nose. The evolution was complicated by a subsequent failure of BMT. Only activated lymphocytes were observed on the bone marrow smears, without viral particles. The lesions became necrotic (Figure 1) . At day +70, a life-threatening laryngeal obstruction occurred requiring a tracheotomy. No improvement was obtained despite high-dose ACV (500 mg/m 2 every 8 h) and the addition of foscarnet (80 mg/kg/day) and later ganciclovir (5 mg/kg every 12 h). Viral cultures performed from a skin biopsy were positive for a strain of HSV-1 which was shown by phenotyping to be resistant in vitro to ACV and foscarnet.
Treatment with cidofovir (5 mg/kg i.v.) was started on day +88. To circumvent nephrotoxicity, each injection was given with saline hydration, and probenecid, 50 mg/kg p.o. 3 h before, then 2 and 6 h after cidofovir injections. The treatment was administered once a week for 3 weeks, then every other week for 2 months.
Due to persisting aplasia, a second BMT was performed 2 days after the first injection of cidofovir without any conditioning regimen. The second BMT was part of the initial harvest, which had been previously frozen.
A spectacular improvement was observed after each dose of cidofovir (5 mg/kg) and the mucous and cutaneous lesions were completely healed after the seventh injection. No recurrence has occurred to date. ACV had never been stopped during the treatment. Rapid bone marrow reconstitution was observed after the second BMT, and only transient proteinuria and a brief generalized rash were observed after each day of treatment. Twelve months after the second BMT the patient is free of HSV-1 infection and leukemia. She is currently being treated for chronic GVHD. She has no renal impairment.
Discussion
The emergence of ACV-resistant HSV infections in severely immuno-compromised patients is a new and challenging problem. In a recent study carried out on a series of 222 patient who underwent BMT, HSV infection was diagnosed in 23 adults and five children. 6 Among these, seven were resistant to ACV. Despite its potential toxicity, cidofovir appears to be an important salvage agent when first-line anti-herpes drugs fail to control infection.
Allogeneic BMT is always associated with transient neutropenia and long-lasting immunodeficiency. 1 Risk of infection is increased by the underlying disease and previous treatments, particularly high-dose chemotherapy. Some drugs such as fludarabine, daunorubicine and cytarabine are responsible for a profound cellular immune deficiency. 7, 8 GVHD prophylaxis with highly efficient immunosuppressive drugs increases and prolongs the risk of opportunistic infections.
Reactivation of latent HSV is frequent after BMT and adds substantially to morbidity. 3 In 70 to 80% of previously seropositive recipients it occurs early, during the first 3 weeks after the end of myeloablative treatment. 1 Reactivation of HSV causes a severe increase in the oral mucositis usually observed after the conditioning regimens used in BMT for hematological malignancies. 9 The infection spreads locally to produce extensive hemorragic ulcerations of adjacent skin and mucous membranes. As in our patient, extension to the larynx may be life-threatening. 1 Systemic dissemination of virus may cause multiple organ failure especially where bone marrow aplasia enhances risk of infections. 1, 10 Reactivation of latent HSV is avoided in 90% of seropositive patients with prophylactic ACV at a dose of 250 mg/m 2 every 8 h. However, clinical resistance to ACV is a growing concern in bone marrow transplant patients. ACV-resistant HSV strains have been isolated from 5 to 10% of patients taking prophylactic therapy, and in these patients, overwhelming infection may lead to multiple organ failure. 10 Usually, ACV-resistant HSV strains emerge as a result of mutations within the viral thymidine kinase. DNA polymerase mutations are less frequent. Thymidine kinase performs the initial phosphorylation step in the intracellular activation of ACV and other antiherpes nucleoside analogues such as ganciclovir, famciclovir and valaciclovir. Foscarnet does not require the viral thymidine kinase for its activity and is currently the only approved treatment for ACV-resistant HSV infections. 2, 11 Failure of foscarnet has previously been described in HIV infections and in hematological malignancies. Cross-resistance to foscarnet suggests either an alteration in the DNA polymerase or a combination of separate HSV drug-resistant populations. Only a restricted number of sites of mutation in the DNA polymerase gene may give drug resistance while maintaining a functional enzyme. 12 Cidofovir (HPMPC, GS504) is a nucleotide analogue with a spectrum against HSV 1 and 2, CMV, VZV, EBV and human papilloma viruses. Cidofovir targets viral DNA polymerase. Unlike ACV or ganciclovir, which require intracellular phosphorylation by a virally encoded enzyme, cidofovir is a monophosphate nucleotide analogue which is phosphorylated into an active form by cellular enzymes independently of any viral participation. Thus, viral mutations leading to altered phosphorylase activity will not result in resistance to cidofovir. Other mechanisms of resistance cannot be excluded. 4, 13 With the long intracellular half-life of its metabolites, cidofovir can be administered weekly during the initial phase of treatment and then every other week until a bone marrow reconstitution is obtained.
11 Proteinuria (83%) and neutropenia (15%) are the most common adverse effects. Administration of probenecid, an uricosuric agent which decreases renal tubular secretion of anionic drugs, and saline hydration reduces the incidence and severity of nephrotoxicity in patients receiving cidofovir. However, probenecid can cause mild to moderate adverse reactions which include nausea, vomiting, headache, fever and flushing. 4 The indications of cidofovir for HSV infections are still under discussion and efficacy and toxicity of cidofovir in children infected with HSV have not been evaluated yet. This drug may be considered as salvage therapy for patients with persisting, life-threatening HSV infections despite high-dose intravenous ACV and foscarnet. 
